New approach, not yet tested in humans, aims to restore immune-powering B cells in cancer patients following successful CAR T-cell therapy
Oct. 17, 2016
| By Bill Briggs / Fred Hutch News Service
Scientists at Fred Hutch, Seattle Children’s Research Institute, and Technical University of Munich showed that activating a “kill switch” can turn off CAR T cells after doctors deem a cancer defeated, allowing normal B cells to again flourish.
Cassian Yee study shows progress in using patients' own tumor-fighting cells to knock back late-stage skin cancer
March 5, 2012
| By Dean Forbes
A small, early-phase clinical trial, led by Dr. Cassian Yee of the Hutchinson Center's Clinical Research Division, to test the effectiveness of treating patients with advanced melanoma using billions of clones of their own tumor-fighting cells combined with a specific type of chemotherapy has shown that the approach has promise. One patient of the 11 experienced a long-term, complete remission that has lasted more than three years, and in four others with progressive disease, the melanoma temporarily stopped growing. The results of the study appear in the March 5 early edition of the Proceedings of the National Academy of Sciences.
Case is first to show safety and effectiveness of using infection-fighting T cells alone to put late-stage melanoma into long-term remission
June 23, 2008
| By Dean Forbes
Scientists from Fred Hutchinson Cancer Research Center describe the first successful use of a human patient’s cloned infection-fighting T-cells as the sole therapy to put an advanced solid-tumor cancer into long-term remission